Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)

Inclusion Criteria: * Indicates no limit on eligibility based on the sex of participants * The 76 years old for the minimum age a potential participant must meet to be eligible for the clinical study. * Esophageal squamous cell carcinoma confirmed by pathology * No radiotherapy, chemotherapy or other treatments prior to enrollment * Local advanced esophageal squamous cell carcinoma (T2-4N0-1M0-1a, TxN1M0-1a, TxNxM1a, TxNxM1b (M1b only for supraclavicular lymph node metastasis) (AJCC 6th) * Use of an effective contraceptive for adults to prevent pregnancy * No severely abnormal hematopoietic, cardiac, pulmonary, renal, or hepatic function * No immunodeficiency * ECOG 0-1. * Life expectancy of more than 3 months. Exclusion Criteria: * Total radiotherapy dose cannot reach 61.2Gy/34Fx * Esophageal perforation, or hematemesis * History of radiotherapy or chemotherapy for esophageal cancer * History of surgery within 28 days before Day 1 * History of prior malignancies (other than skin basal cell carcinoma or cervical carcinoma in situ with a disease-free survival of at least 3 years) * Participation in other interventional clinical trials within 30 days * Pregnant or breast-feeding women or fertile patients * Drug addiction, * alcoholism or AIDS * Uncontrolled seizures or psychiatric disorders